UNSPSC 51162202: Acetaminophen/caffeine/phenylpropanolamine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE900. This VA Drug Class (RE900) classifies this compound as belonging to the group RESPIRATORY AGENTS, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162202 Acetaminophen/caffeine/phenylpropanolamine/pyrilamine is a Commodity code covering branded and generic combination pain-relief and cold-symptom formulations supplied to state and local government healthcare and institutional facilities. State and local governments procure these products as components of broader pharmaceutical sourcing contracts, typically bundled with other OTC and generic drugs under cooperative purchasing agreements that establish wholesale pricing and supply relationships across multiple jurisdictions and facility types. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, is a primary issuing body for this commodity, leveraging cooperative vehicles to distribute contracts across participating state agencies, counties, and municipalities in Minnesota and Oregon.

The code shows recent activity concentrated in the Upper Midwest, with MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (solicitation S1070000015802, due March 26, 2026) as the most recent state-local opportunity under this code. The RFP establishes multiple contracts for pharmaceutical manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026. Vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three wholesalers, carry $5 million commercial general liability insurance, and submit pricing in flat-price, net-price, or WAC-minus formats. Pricing competitiveness weights 75 percent of evaluation, with fixed pricing, administrative-format compliance, EDI capability, and the mandatory 3 percent administrative fee comprising the remaining 25 percent. The contract term is two years for new responders with optional MMCAP extensions, while incumbent vendors' amendments extend through June 30, 2028.